Skip to Content

SpringWorks Therapeutics Inc Ordinary Shares SWTX

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

SpringWorks Therapeutics Inc is a United States-based biopharmaceutical company. It is focused on identifying, developing, and commercializing therapies for underserved patient populations suffering from severe rare diseases and cancer. The firm's pipeline product includes Mirdametinib, Nirogacestat, and others.

Contact
100 Washington Boulevard
Stamford, CT, 06902
T +1 203 883-9490
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Sep 30, 2021
Fiscal Year End Dec 31, 2021
Stock Type
Employees 142